Michele's 2023 United Airlines NYC Half Marathon Fundraising Page
Michele Abascal
Michele Abascal
Right now, 37 million American adults are living with kidney disease, and I’m not okay with that. I run because 1 in 3 people are at risk for kidney disease. I run because more than 1 in 7 people have it but aren’t aware.
I run to raise funds that support the National Kidney Foundation, who was the first to identify kidney disease as a distinct, treatable illness. They developed the staged system of kidney disease diagnosis and treatment – a worldwide standard today – and release and update treatment guidelines to improve patient care.
Join me in making these advances possible by donating to my efforts!
Thank you for your support!
Why I Run
My brother Steven was diagnosed April 2022 with FSGS (Focal segmental glomerulosclerosis)- a rare kidney disease causing him stage 5 end-stage kidney failure.
I run to raise funds that support the National Kidney Foundation, who was the first to identify kidney disease as a distinct, treatable illness. They developed the staged system of kidney disease diagnosis and treatment – a worldwide standard today – and release and update treatment guidelines to improve patient care.
Join me in making these advances possible by donating to my efforts!
Thank you for your support!
Why I Run
My brother Steven was diagnosed April 2022 with FSGS (Focal segmental glomerulosclerosis)- a rare kidney disease causing him stage 5 end-stage kidney failure.
He is currently on dialysis 3 times a week, for four hours each time, in order to keep his kidneys & full body functioning.
The only treatment at this point would be a kidney transplant. The wait to get on the transplant list was stalled while waiting for insurance to be corrected in order to cover the transplant. The Medicare insurance has been corrected & the transplant will now be covered. He will be back on the transplant list very soon.
If you’d like to learn about or become a living donor, you can go to: http://www.columbiakidneytransplant.org/.
Comments